Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer.
Christopher J M WilliamsFaye ElliottNancy SapanaraFaranak AghaeiLiping ZhangAndrea MuranyiDongyao YanIsaac BaiZuo ZhaoMichael ShiresHenry M WoodSusan D RichmanGemma HemmingsMichael HaleDaniel BottomleyLeanne GalvinCaroline CartlidgeSarah DanceChris M BaconLaura MansfieldKathe Young-ZvandasaraAjay SudanKaty LambertIrena BibbySarah E CouplandAmir MontazeriNatalie KiplingKathryn HughesSimon S CrossAlice DewdneyLeanne PheaseyCathryn LengTatenda GocheraD Chas ManghamMark SaundersMartin PritchardHelen StottAbhik MukherjeeMohammad IlyasRafael SilvermanGeorgina HylandDeclan SculthorpeKirsty ThorntonImogen GouldAnn O'CallaghanNicholas BrownSamantha J TurnbullLisa ShawMatthew T SeymourNicholas P WestJenny F SeligmannShalini SinghKandavel ShanmugamPhilip QuirkePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
High tumor AREG/EREG expression was associated with superior survival outcomes from anti-EGFR therapy in mCRC, including in right PTL disease. AREG/EREG IHC assessment could aid therapeutic decisions in routine practice.